Radiation and immunotherapy combo targets untreatable liver tumors
NCT ID NCT07482059
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of internal radiation (Y90-SIRT) with three drugs (nivolumab, ipilimumab, and lenvatinib) in 33 people with liver cancer that cannot be surgically removed. The goal is to see if this powerful mix is safe and can shrink tumors or extend survival. It is an early-stage trial, so the main focus is on safety and finding the right doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 microspheres, nivolumab, ipilimumab, and lenvatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply to everyone. The combination of multiple drugs and radiation may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study Chair Liu Chang , West China Hospital
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••